Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 9/20 | 0.50 |
| ▸ | JAK2 | O60674 | 6/20 | 0.50 |
| ▸ | IGF1R | P08069 | 5/20 | 0.48 |
| ▸ | JAK3 | P52333 | 4/20 | 0.48 |
| ▸ | AURKA | O14965 | 2/20 | 0.48 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.48 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | LTK | P29376 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.48 |
| ▸ | CLK2 | P49760 | 1/20 | 0.48 |
| ▸ | CDK7 | P50613 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218889 | 0.79 | IGF1R (0.44) | NTRK1JAK2IGF1RJAK3FGFR1 | |
| SCHEMBL4068386 | 0.76 | MEN1 (0.49) | NTRK1JAK2IGF1RFGFR1KDR | |
| SCHEMBL3930199 | 0.74 | JAK2 (0.49) | NTRK1JAK2IGF1RJAK3AURKA | |
| SCHEMBL589661 | 0.72 | IGF1R (0.46) | NTRK1IGF1R | |
| SCHEMBL4033781 | 0.72 | IGF1R (0.57) | NTRK1JAK2IGF1RJAK3FGFR1 | |
| SCHEMBL29190641 | 0.71 | IGF1R (0.51) | IGF1RLRRK2ALKMEN1KMT2A | |
| SCHEMBL219273 | 0.69 | IGF1R (0.62) | JAK2IGF1RJAK3FGFR1KDR | |
| SCHEMBL217975 | 0.69 | IGF1R (0.45) | IGF1RFGFR1KDRMEN1KMT2A | |
| SCHEMBL3452623 | 0.68 | MEN1 (0.42) | LRRK2MEN1KMT2A | |
| SCHEMBL17304181 | 0.67 | PLK4 (0.36) | NTRK1JAK2IGF1RJAK3AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | NTRK1 4728/4885JAK2 2137/4885IGF1R 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.